Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Paul Hudson

CEOPaul Hudson

Employees

84,587

Employees84,587

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

84,587

Employees84,587

SNY Key Statistics

Market cap

114.27B

Market cap114.27B

Price-Earnings ratio

11.58

Price-Earnings ratio11.58

Dividend yield

3.43%

Dividend yield3.43%

Average volume

3.89M

Average volume3.89M

High today

$47.03

High today$47.03

Low today

$46.49

Low today$46.49

Open price

$46.93

Open price$46.93

Volume

2.64M

Volume2.64M

52 Week high

$60.12

52 Week high$60.12

52 Week low

$44.62

52 Week low$44.62

SNY News

TipRanks 4d

Sanofi price target lowered to EUR 105 from EUR 110 at Deutsche Bank

Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Sanofi (SNY) to EUR 105 from EUR 110 and keeps a Buy rating on the shares. Claim 70...

TipRanks 4d

Sanofi Targets Pfizer’s Pneumococcal Stronghold With New Phase 3 Infant Vaccine Trial

Sanofi SA (SNY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools fo...

TipRanks 4d

Sanofi Advances Next-Gen Respiratory Vaccines With Completed Phase 1 Multi-Virus Study

Sanofi (SNYNF) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...

More SNY News

TipRanks 5d

Sanofi’s Teplizumab Study Tracks Real-World Impact in Early Type 1 Diabetes

Sanofi SA (SNY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Sanofi Tracks Real-World Impact of Teplizumab in Early Typ...

TipRanks 5d

Sanofi and Regeneron Withdraw Pediatric Dupilumab Growth Study: What Investors Should Know

Sanofi SA (SNY), Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Sanofi and Regeneron rec...

TipRanks 5d

Sanofi prepping higher bid for Ocular Therapeutix, IBD reports

Sanofi (SNY) is preparing to launch an improved bid for Ocular Therapeutix (OCUL), Investor’s Business Daily’s Allison Gatlin reports. Ocular CEO Pravin Dugel p...

Investor's Business Daily 5d

Ocular Therapeutix Launches On Rumors Sanofi Is Preparing A Bigger Bid

Technology Ocular Therapeutix Launches On Rumors Sanofi Is Preparing A Bigger Bid Licensing Shares of Ocular Therapeutix (OCUL) launched Thursday on reports San...

TipRanks 6d

Sanofi Terminates Early-Stage SAR444200 Cancer Trial: What Investors Need to Know

Sanofi (SNYNF) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: Sanofi’s terminated Phase 1/2 study, offici...

TipRanks 6d

Sanofi’s Pediatric Eliglustat Trial Completion: What It Means for Gaucher Franchise Growth

Sanofi (SNYNF) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...

TipRanks 7d

Sanofi Advances Balinatunfib With New Cardiac Safety Study in Healthy Volunteers

Sanofi SA (SNY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools fo...